{"nctId":"NCT00129545","briefTitle":"WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation","startDateStruct":{"date":"2005-02"},"conditions":["Atrial Fibrillation","Stroke"],"count":800,"armGroups":[{"label":"WATCHMAN","type":"EXPERIMENTAL","interventionNames":["Device: WATCHMAN Left Atrial Appendage Closure Technology"]},{"label":"Warfarin control","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Warfarin"]},{"label":"Roll-in","type":"OTHER","interventionNames":["Device: WATCHMAN Left Atrial Appendage Closure Technology"]}],"interventions":[{"name":"WATCHMAN Left Atrial Appendage Closure Technology","otherNames":["WATCHMAN"]},{"name":"Warfarin","otherNames":["Coumadin"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient has paroxysmal, persistent or permanent non-valvular atrial fibrillation (AF)\n* Eligible for long term warfarin\n* CHADS score \\>= 1 \\[congestive heart failure (CHF), history of high blood pressure, 75 years of age or older, diabetes, prior stroke or transient ischemic attack (TIA)\\]\n\nExclusion Criteria:\n\n* Contraindicated for warfarin\n* Contraindicated for aspirin or clopidogrel (Plavix)\n* Congestive heart failure (CHF) Class 4\n* Implanted mechanical valve\n* Atrial septal or Patent Foramen Ovale (PFO) device\n* Platelets \\< 100,000 or hemoglobin \\< 10\n* Left ventricular ejection fraction (LVEF) \\< 30%","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Composite of Stroke, Systemic Embolism and Cardiovascular or Unexplained Death","description":"A Bayesian model allowed for sequential evaluation of the primary endpoints, event rates reported per 100 patient-years (calculated as 100\\*N events/Total patient-years)","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":null},{"groupId":"OG001","value":"3.7","spread":null}]}]}]},{"type":"PRIMARY","title":"The Occurrence of Life-threatening Events, Including Device Embolization or Serious Bleeding Events","description":"Serious bleeding events evaluated by the Clinical Events Committee included pericardial effusion requiring drainage, cranial bleeding events due to any source, gastrointestinal bleeds requiring transfusion, and any bleeding related to the device or procedure that necessitates an operation.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":null},{"groupId":"OG001","value":"3.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Procedure Success","description":"Implant procedure success is defined as the delivery and release of a WATCHMAN Device into the LAA.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":29,"n":93},"commonTop":["Other Study Related","Epistaxis","Device Thrombus","Pericardial Effusion","Rectal Bleeding"]}}}